miércoles, 28 de octubre de 2009

El "twitter"...tambien se paga.

Boehringer-Ingelheim (BI), the German pharma company, just posted the following branded Tweet via Twitter. The link in that Tweet leads to this press release, which provides the details, including fair balance (eg, side effects). Namely, it mentions BOTH the product name AND the indication without including within it the fair balance. It is, therefore, very similar to the paid search ads that the FDA said violated the law (see "FDA's Actions Speak Louder than Its Words: On the Internet It's the Medium as Well as the Message!"). Tomé "prestado" de John Mack

No hay comentarios: